Canrenoate

Summary

Canrenoate (CHEMBL1616951) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 358.5 Da · C22H30O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1616951
Name	Canrenoate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	656615
ChEBI	CHEBI:50156
Molecular formula	C22H30O4
Molecular weight	358.5
InChIKey	PBKZPPIHUVSDNM-WNHSNXHDSA-N

SMILES: C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(CCC(=O)O)O)C

IUPAC name: 3-[(8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoic acid

Also known as: Acide canrenoique, Acido canrenoico, Canrenoic acid, canrenoate, CANRENOIC ACID, CANRENOATE

Parent form; salt/anhydrous children: CHEMBL1371200

Patent coverage: 192 distinct patent families (568 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).